Bliss GVS Pharma Limited has strengthened its board governance by appointing two seasoned professionals as Independent Directors and has now issued a postal ballot notice seeking shareholder approval. The pharmaceutical company announced through a board resolution dated April 03, 2026, that it has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Non-Executive Independent Directors for five-year terms.

Postal Ballot Notice Details

The company issued a postal ballot notice on April 09, 2026, to both NSE and BSE for seeking member approval through remote e-voting process. The notice has been sent electronically to shareholders whose email addresses are registered with MUFG Intime India Private Limited (formerly Link Intime India Private Limited), the company's Registrar and Share Transfer Agent.

Board Resolution and Appointments

The Board of Directors, acting on the recommendation of the Nomination and Remuneration Committee, passed resolutions by circulation on April 03, 2026. Both appointments require special resolution approval from shareholders through the postal ballot process.

Profile of New Directors

Mr. Vijayanarayanan Mahadevan (DIN: 06639177)

Mr. Mahadevan brings extensive financial leadership experience spanning over 35 years across multiple organizations and geographies. As a Chartered Accountant, he has worked with prominent companies including Alcon, Sandoz, Novartis, and SHV Energy. His expertise encompasses establishing finance functions for new businesses across manufacturing, trading, and R&D environments, strategic financial leadership, and successfully turning around loss-making businesses into profitable operations.

Mr. Deepak Rameshchandra Shah (DIN: 06954206)

Mr. Shah is a Fellow Member of the Institute of Chartered Accountants of India (ICAI) with over 36 years of experience in taxation and audit. Based in Mumbai, he has held several key leadership positions including Former President of the Bombay Chartered Accountants' Society, Former Chairman of the Western Zone of AIFTP, and currently serves as Chairman of the Direct Taxation Committee of BCAS. He is also an Independent Director on boards of The Ruby Mills Limited, Marathon Nextgen Realty Limited, and Siyaram Silk Mills Limited.

Regulatory Compliance and Voting Process

Both directors have been confirmed as not being debarred from holding director positions by SEBI or any other regulatory authority. The appointments comply with SEBI regulations and related master circulars. The postal ballot notice is available on the company's website at www.blissgvs.com/postal-ballot and shareholders can vote through CDSL's remote e-voting platform.

The appointments will be effective for the full five-year term once shareholders provide their consent through the postal ballot process, with results to be declared on or before May 12, 2026.

Bliss GVS Pharma Limited has announced that ICRA Limited has assigned credit ratings to the company's banking facilities worth Rs. 100.00 crore. The pharmaceutical company informed both the National Stock Exchange and BSE Limited about this development on April 08, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Credit Rating Details

ICRA Limited has assigned the following ratings to Bliss GVS Pharma's banking facilities:

The rating assignment was communicated through ICRA's letter dated April 08, 2026, bearing reference number ICRA/Bliss GVS Pharma Limited/08042026/1. The rating covers facilities provided by Federal Bank Limited and was assigned on April 07, 2026.

Rating Surveillance and Terms

According to ICRA's communication, the assigned ratings will become due for surveillance within one year from the date of the rating communication letter. The rating agency has reserved the right to review and revise the ratings at any time based on new information becoming available or other circumstances that could impact the ratings.

The ratings are specific to the current terms and conditions of the instruments as indicated by the company. Any changes in the terms, conditions, or size of the rated instruments would require a review by ICRA. The company is required to inform ICRA about any defaults, delays in repayment, or significant developments that could impact debt servicing capability.

Regulatory Compliance

Bliss GVS Pharma's Company Secretary Aditi Bhatt signed the regulatory filing, ensuring compliance with stock exchange listing requirements. The company has provided complete documentation including ICRA's rating letter to both NSE and BSE for their records.

The rating assignment provides the company with formal credit assessment for its banking facilities, which supports its financial operations and lending arrangements with Federal Bank Limited.